A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131
- PMID: 24867985
- PMCID: PMC4135879
- DOI: 10.1128/AAC.02824-14
A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131
Abstract
Escherichia coli sequence type 131 (ST131) is an extensively antimicrobial-resistant E. coli clonal group that has spread explosively throughout the world. Recent molecular epidemiologic and whole-genome phylogenetic studies have elucidated the fine clonal structure of ST131, which comprises multiple ST131 subclones with distinctive resistance profiles, including the (nested) H30, H30-R, and H30-Rx subclones. The most prevalent ST131 subclone, H30, arose from a single common fluoroquinolone (FQ)-susceptible ancestor containing allele 30 of fimH (type 1 fimbrial adhesin gene). An early H30 subclone member acquired FQ resistance and launched the rapid expansion of the resulting FQ-resistant subclone, H30-R. Subsequently, a member of H30-R acquired the CTX-M-15 extended-spectrum beta-lactamase and launched the rapid expansion of the CTX-M-15-containing subclone within H30-R, H30-Rx. Clonal expansion clearly is now the dominant mechanism for the rising prevalence of both FQ resistance and CTX-M-15 production in ST131 and in E. coli generally. Reasons for the successful dissemination and expansion of the key ST131 subclones remain undefined but may include increased transmissibility, greater ability to colonize and/or persist in the intestine or urinary tract, enhanced virulence, and more-extensive antimicrobial resistance compared to other E. coli. Here we discuss the epidemiology and molecular phylogeny of ST131 and its key subclones, possible mechanisms for their ecological success, implications of their widespread dissemination, and future research needs.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.
Figures

Similar articles
-
The epidemic of extended-spectrum-β-lactamase-producing Escherichia coli ST131 is driven by a single highly pathogenic subclone, H30-Rx.mBio. 2013 Dec 17;4(6):e00377-13. doi: 10.1128/mBio.00377-13. mBio. 2013. PMID: 24345742 Free PMC article.
-
Temporal trends in antimicrobial resistance and virulence-associated traits within the Escherichia coli sequence type 131 clonal group and its H30 and H30-Rx subclones, 1968 to 2012.Antimicrob Agents Chemother. 2014 Nov;58(11):6886-95. doi: 10.1128/AAC.03679-14. Epub 2014 Sep 8. Antimicrob Agents Chemother. 2014. PMID: 25199783 Free PMC article.
-
The clinical impact of ST131 H30-Rx subclone in urinary tract infections due to multidrug-resistant Escherichia coli.J Glob Antimicrob Resist. 2016 Mar;4:49-52. doi: 10.1016/j.jgar.2015.10.006. Epub 2015 Nov 14. J Glob Antimicrob Resist. 2016. PMID: 27436393
-
Escherichia coli ST131: The quintessential example of an international multiresistant high-risk clone.Adv Appl Microbiol. 2015;90:109-54. doi: 10.1016/bs.aambs.2014.09.002. Epub 2014 Nov 13. Adv Appl Microbiol. 2015. PMID: 25596031 Review.
-
Tackling Drug Resistant Infection Outbreaks of Global Pandemic Escherichia coli ST131 Using Evolutionary and Epidemiological Genomics.Microorganisms. 2015 May 20;3(2):236-67. doi: 10.3390/microorganisms3020236. Microorganisms. 2015. PMID: 27682088 Free PMC article. Review.
Cited by
-
Preclinical Immunogenicity and Efficacy of Optimized O25b O-Antigen Glycoconjugates To Prevent MDR ST131 E. coli Infections.Infect Immun. 2022 Apr 21;90(4):e0002222. doi: 10.1128/iai.00022-22. Epub 2022 Mar 21. Infect Immun. 2022. PMID: 35311580 Free PMC article.
-
To kill or to be killed: pangenome analysis of Escherichia coli strains reveals a tailocin specific for pandemic ST131.BMC Biol. 2022 Jun 16;20(1):146. doi: 10.1186/s12915-022-01347-7. BMC Biol. 2022. PMID: 35710371 Free PMC article.
-
Efficacy and safety of ceftazidime/avibactam in patients with infections caused by β-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme.J Antimicrob Chemother. 2023 Nov 6;78(11):2672-2682. doi: 10.1093/jac/dkad280. J Antimicrob Chemother. 2023. PMID: 37700689 Free PMC article. Clinical Trial.
-
"One Health" perspective on prevalence of co-existing extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae: a comprehensive systematic review and meta-analysis.Ann Clin Microbiol Antimicrob. 2023 Sep 22;22(1):88. doi: 10.1186/s12941-023-00638-3. Ann Clin Microbiol Antimicrob. 2023. PMID: 37740207 Free PMC article. Review.
-
Evaluation of MLVA for epidemiological typing and outbreak detection of ESBL-producing Escherichia coli in Sweden.BMC Microbiol. 2017 Jan 6;17(1):8. doi: 10.1186/s12866-016-0922-1. BMC Microbiol. 2017. PMID: 28061803 Free PMC article.
References
-
- Coque TM, Baquero F, Canton R. 2008. Increasing prevalence of ESBL-producing enterobacteriaceae in Europe. Euro Surveill. 13:19044 http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19044 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources